Ala54Thr Polymorphism of Fatty Acid Binding Protein 2, Role on Insulin Resistance and Cardiovascular Risk Factors in Presurgical Morbid Obesity Patients

Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation, Hospital Rio Hortega, University of Valladolid, RD056/00013 RETICEF, Valladolid, Spain.
Obesity Surgery (Impact Factor: 3.74). 06/2009; 19(12):1691-6. DOI: 10.1007/s11695-009-9859-x
Source: PubMed

ABSTRACT A transition G to A at codon 54 of fatty acid binding protein 2 (FABP2) results in an amino acid substitution (ala 54 to Thr 54). This polymorphism was associated with insulin resistance in some populations.
The aim of our study was to investigate the influence of Thr54 polymorphism in the FABP2 gene on obesity anthropometric parameters, cardiovascular risk factors, and adipocytokines in patients with presurgical morbid obesity.
A population of 55 morbid obese patients was enrolled. An indirect calorimetry, tetrapolar electrical bioimpedance, blood pressure, a serial assessment of nutritional intake with 3 days of written food records, and biochemical analysis (lipid profile, adipocytokines, insulin, C-reactive protein, and lipoprotein-a) were performed. The statistical analysis was performed for the combined Ala54/Thr54 and Thr54/Thr54 as a mutant-type group and wild-type group (Ala54/Ala54).
Twenty nine (52.7%) had the genotype Ala54/Ala54 (wild-type group) and 26 (47.3%) patients had the genotype Ala54/Thr54 (24 patients, 43.7%) or Thr54/Thr54 (two patients, 3.6%; mutant-type group). Insulin (22.4 +/- 16.8 vs. 26.1 +/- 17.1 mg/dl; p = 0.04) and homeostasis model assessment (6.1 +/- 2.1 vs. 6.7 +/- 4.5; p = 0.04) levels were higher in mutant-type group than wild-type group. In mutant-type group, leptin levels (134.8 +/- 83 vs. 206.5 +/- 76 ng/ml; p = 0.03) were higher than wild-type group. Moreover, adiponectin levels (80.9 +/- 39.6 vs. 23.9 +/- 13.8 ng/ml; p = 0.02) were higher in wild-type group than mutant-type group.
The novel finding of this study is the association of Thr54 allele with insulin resistance, leptin, and adiponectin levels in morbidly obese patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Hypertension has a multi-factorial background based on genetic and environmental interactive factors. ACE, FABP2 and GST genes have been suggested to be involved in the development of hypertension. However, the results have been inconsistent. Aim: The present study was carried out to investigate the association of ACE (rs4646994), FABP2 (rs1799883) and GST (GSTM1 null or positive genotype and GSTT1 null or positive genotype) genes polymorphism with essential HTN cases and controls. Subjects and methods: This study includes 138 essential hypertension (HTN) patients and 116 age-, sex- and ethnicity-matched control subjects. GST (GSTM1 null or positive genotype and GSTT1 null or positive genotype) genes polymorphisms were evaluated by multiplex PCR, ACE (rs4646994) gene polymorphisms by PCR and FABP2 (rs1799883) gene polymorphisms by PCR-RFLP method. Results: Significant differences were obtained in the frequencies of ACE DD, II genotype (p = 0.006, 0.003), GSTT1 null, GSTM1 positive genotype (p = 0.048, 0.010) and FABP2 Ala54/Ala54 genotype (p = 0.049) between essential HTN cases and controls. Conclusion: It is concluded that ACE (rs 4646994), FABP2 (rs1799883) and GST (GSTM1 null or positive genotype and GSTT1 null or positive genotype) genes polymorphism are associated with HTN. Further investigation with a larger sample size may be required to validate this study.
    Annals of Human Biology 10/2014; DOI:10.3109/03014460.2014.968206 · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of fatty acid-binding proteins in cardiovascular disease has been the subject of several studies and viewpoints in recent years. These proteins are involved in the atherosclerotic plaque formation mainly in macrophages through a complex processing of lipids and inflammatory responses. In addition, they may signal the presence of obesity, insulin resistance, and type 2 diabetes mellitus, co-morbidities with a demonstrated impact in cardiovascular risk. The present review aims to summarize the most relevant findings over the past years to the function of fatty acid-binding proteins (FABPs) along the spectrum of metabolic disorders and cardiovascular disease. Finally, we will discuss the potential use of FABPs as cardiovascular risk markers and therapeutic targets to halt the progression of atherosclerosis.
    Current Cardiovascular Risk Reports 01/2013; 7(1). DOI:10.1007/s12170-012-0287-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: The results from the published studies on the association of fatty acid-binding protein 2 (FABP2) Ala54Thr polymorphism with dyslipidemia are conflicting and inconclusive. In this meta-analysis encompassing all the relevant studies, we aimed to investigate the association of the FABP2 Ala54Thr polymorphism with fasting blood lipids. We limited our analysis to the following four blood lipid parameters: total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). Subjects were confined to adults who were at least 18 years old. A dominant model was used for this meta-analysis. 30 studies with 14,401 subjects were included in this meta-analysis. The results showed that the carriers of Thr54 allele have higher blood TC and LDL-C than the non-carriers: standardized mean difference (SMD)=0.07, 95% CI (confidence interval, 0.02, 0.11), P=0.005, Pheterogeneity=0.12, and SMD=0.09, 95% CI (0.03, 0.15), P=0.002, Pheterogeneity=0.0006, respectively. Significant association between the Ala54Thr polymorphism and lower blood HDL-C was also detected under the dominant models: SMD=-0.05, 95% CI (-0.09, -0.00), P=0.04, Pheterogeneity=0.10. Our meta-analysis supports the strong association between the Thr54 allele of the FABP2 Ala54Thr polymorphism with higher levels of TC and LDL-C, and lower levels of HDL-C.
    Atherosclerosis 06/2010; 210(2):461-7. DOI:10.1016/j.atherosclerosis.2009.11.049 · 3.97 Impact Factor